Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans
News
Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita
Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK
Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes
– Last subject randomized in Phase 2b study-
– Study randomized 433 subjects across 61 sites in 2 countries-
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology
VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
VenatoRx is eligible to receive up to $114 million, including upfront milestone payments, in addition to royalties